NIOX Group (LON:NIOX) Shares Up 3.8% - Here's What Happened

Key Points

• NIOX Group shares increased by 3.8% on Wednesday, trading at GBX 72.23 ($0.98) after closing at GBX 69.60 ($0.94).
• The company, with a market capitalization of £29.67 billion, has a high price-to-earnings ratio of 2,980.72 and insider ownership of 46.72%.
• NIOX Group focuses on non-invasive diagnostic products for chronic respiratory diseases, improving management of conditions like asthma and COPD.

NIOX Group Plc (LON:NIOX - Get Free Report)'s stock price was up 3.8% during trading on Wednesday . The stock traded as high as GBX 73 ($0.98) and last traded at GBX 72.23 ($0.97). Approximately 852,805 shares were traded during mid-day trading, a decline of 22% from the average daily volume of 1,094,688 shares. The stock had previously closed at GBX 69.60 ($0.93).

NIOX Group Stock Performance

The company's 50-day moving average price is GBX 69.54 and its 200 day moving average price is GBX 67.10. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.94 and a current ratio of 6.31. The stock has a market capitalization of £304.72 million, a PE ratio of 8,795.18 and a beta of 0.92.

Insider Activity at NIOX Group

In related news, insider Ian Johnson bought 144,844 shares of the company's stock in a transaction dated Wednesday, June 25th. The stock was purchased at an average cost of GBX 8 per share, with a total value of £11,587.52. Corporate insiders own 4.89% of the company's stock.

About NIOX Group

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange ticker: NIOX, the company operates internationally, serving healthcare professionals in over 50 countries.